Enter Details

Comment on stories, receive email newsletters & alerts.

This is your permanent identity for Business Insider Australia
Your email must be valid for account activation
Minimum of 8 standard keyboard characters


Email newsletters but will contain a brief summary of our top stories and news alerts.

Forgotten Password

Enter Details

Back to log in

This Australian biotech company successfully treated arthritis in a trial and its shares are going wild

John Moore/Getty Images

A trial of Mesoblast’s stem cell product has been show to be effective for rheumatoid arthritis.

The company announced the first results a trial giving 48 rheumatoid arthritis patients an intravenous infusion of Mesoblast’s proprietary Mesenchymal Precursor Cell product.

The treatment resulted in early and sustained clinical responses.

A short time ago, Mesoblast’s shares were up 13% to $1.317.

The global market for rheumatoid arthritis treatmentis is about $15.7 billion. About one third of patients either do not sufficiently respond or cannot tolerate current treatments.

“We are encouraged by the efficacy signals seen in the initial results using the lower dose of Mesoblast’s cell therapy in biologic refractory patients with rheumatoid arthritis,” says Mesoblast CEO Silviu Itescu.

“They suggest that a single intravenous administration of our cell therapy may result in rapid and sustained responses in patients with active disease where disease
remission remains the clear goal.”

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at